A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617 ; volume:14 ; number:1 ; day:28 ; month:10 ; year:2024 ; pages:1-9 ; date:12.2024
Scientific reports ; 14, Heft 1 (28.10.2024), 1-9, 12.2024
- Creator
-
Wu, Shangrong
Hu, Wenjin
Chen, Mingzhe
Xiao, Xiong
Liu, Ranlu
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-77889-3
- URN
-
urn:nbn:de:101:1-2501172108419.851252352540
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wu, Shangrong
- Hu, Wenjin
- Chen, Mingzhe
- Xiao, Xiong
- Liu, Ranlu
- SpringerLink (Online service)
Other Objects (12)
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events
Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)
Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events
Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)
Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events
Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)